Research Grade Sotigalimab

The FDA has granted an orphan drug designation to sotigalimab (APX005M) as a potential therapeutic option for patients with soft tissue sarcoma, according to announcement from Apexigen Inc., the drug developer. A novel, humanized monoclonal antibody, sotigalimab was designed stimulate antitumor immune response and to target CD40, which is a key co-stimulatory receptor that serves to activate innate and adaptive immune systems. When sotigalimab binds to CD40 on antigen-presenting cells, it induces a multifaceted immune response that brings several components of the immune system together to attack the cancer.

Product Specifications

Product Name Alternative

APX005M, APX-005, APX-005-M, APX-005M, CAS: 2305607-45-6

Accession Number

P25942

Expression System

Mammalian Cells

Reactivity

Human

Applications

Research Grade Biosimilar

Stability

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks) . Store at -20°C 12 months. Store at -80°C long term.